Moreover, a synthetic lethality relationship between other SWI/SNF components including ARID1A and EZH2 has been revealed in several tumor entities [21,22] but the potential of this concept for urothelial bladder cancer therapy is not known. This evidence concerns the gene EZH2 and bladder transitional cell carcinoma.